Previous studies showed that introduction of GCS gene knock-in conferred cancer cell resistance to commonly used chemotherapeutic agents, and conversely, that suppressing GCS activity either directly with GCS inhibitors, or by silencing its expression, sensitized cancer cells to these anticancer agents [1,21,22,23,24]. The gene discussed is UGCG; the disease is cancer.